News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nippon Shinyaku Co., Ltd. And Innovive Pharmaceuticals, Inc. Conclude Licensing Agreement For NS-187, Drug Candidate For Chronic Myelogenous Leukemia


1/6/2006 10:38:14 AM

Tokyo (JCN) Jan 6, 2006 - Nippon Shinyaku announced on January 5 that it concluded a licensing agreement with INNOVIVE Pharmaceuticals of New York on December 28, 2005. Under the agreement terms, INNOVIVE Pharmaceuticals will be licensed to exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan.

Read at JCN Newswire


comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES